CPE, Mirae lead $100m Series B for China's JW Therapeutics
JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China’s WuXi AppTec, has received $100 million in Series B funding.
The round was led by CPE – formerly CITIC Private Equity – and Mirae Asset. Additional commitments came from Oriza Holdings and CR-CP Life Science Fund, a $300 million life sciences vehicle established...
More on Greater China
Latest News
Q&A: Circulate Capital's Rob Kaplan
Rob Kaplan is CEO of Singapore’s Circulate Capital, which is dedicated to reducing oceanic plastic pollution. Its $150 million debut fund is backed by the likes of Coca-Cola, PepsiCo, and Unilever
Australia's Blackbird raises $357m for fourth fund
Australia’s Blackbird Ventures has raised A$500 million ($357 million) for its fourth fund and named Atlassian co-founder Mike Cannon-Brookes as chairman.
Chinese CRO player Yaoyanshe raises $86m
Yaoyanshe, a Chinese contract research organization (CRO) for novel drugs, has raised RMB600 million ($86 million) across two rounds in the past eight months.
India cosmetics brand MyGlamm acquires content platform
MyGlamm, an online Indian cosmetics brand, has agreed to acquire POPxo, a women-focused content platform, for an undisclosed sum. Both companies have several VC backers.